Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun 2;31(6):1043-1045.
doi: 10.1016/j.cmet.2020.05.009.

A Sympathetic Treatment for Obesity

Jung Dae Kim  1 , Sabrina Diano  2
Affiliations
Comment

A Sympathetic Treatment for Obesity

Jung Dae Kim et al. Cell Metab. .

Abstract

Amphetamine (AMPH), mainly used in the treatment of attention deficit hyperactivity disorder and narcolepsy, has weight loss properties, although with detrimental cardiovascular effects. In this issue, Mahú et al. (2020) describe the effect of a new derivative of AMPH, "PEGyAMPH," a brain-spared anti-obesity drug that alters sympathetic activity without cardiovascular side effects.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Effects of AMPH and PEGyAMPH in Regulating Body Weight
Schematic showing central and sympathetic effects of AMPH and PEGyAMPH in regulating body weight. Peripheral treatment of AMPH affects food intake, locomotor activity, lipolysis, and thermogenesis through central and sympathetic stimulations. However, peripheral treatment of PEGyAMPH affects only lipolysis and thermogenesis via sympathetic action. Of note, PEGyAMPH-treated mice maintained normothermia by heat dissipation through tail vasodilation while AMPH-treated mice developed hyperthermia. Nevertheless, both AMPH and PEGyAMPH showed anti-obesity effects. BAT, brown adipose tissue.
See this image and copyright information in PMC

Comment on

  • Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects.
    Mahú I, Barateiro A, Rial-Pensado E, Martinéz-Sánchez N, Vaz SH, Cal PMSD, Jenkins B, Rodrigues T, Cordeiro C, Costa MF, Mendes R, Seixas E, Pereira MMA, Kubasova N, Gres V, Morris I, Temporão C, Olivares M, Sanz Y, Koulman A, Corzana F, Sebastião AM, López M, Bernardes GJL, Domingos AI. Mahú I, et al. Cell Metab. 2020 Jun 2;31(6):1120-1135.e7. doi: 10.1016/j.cmet.2020.04.013. Epub 2020 May 12. Cell Metab. 2020. PMID: 32402266 Free PMC article.

References

    1. Kuczenski R, Segal DS, Cho AK, and Melega W (1995). Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 15, 1308–1317. - PMC - PubMed
    1. Mahú I, Barateiro A, Rial-Pensado E, Martinéz-Sánchez N, Vaz SH, Cal PMSD, Jenkins B, Rodrigues T, Cordeiro C, Costa MF, et al. (2020). Brain-sparing sympathofacilitators mitigate obesity without adverse cardiovascular effects. Cell Metab. 31, this issue, 1120–1135. - PMC - PubMed
    1. Pereira MM, Mahú I, Seixas E, Martiné z-Sánchez N, Kubasova N, Pirzgalska RM, Cohen P, Dietrich MO, López M, Bernardes GJ, and Domingos AI (2017). A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages. Nat. Commun. 8, 14967. - PMC - PubMed
    1. Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, and Horowitz BZ (2015). Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug Alcohol Depend. 150, 1–13. - PubMed
    1. Rothman RB, Partilla JS, Baumann MH, Dersch CM, Carroll FI, and Rice KC (2000). Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 35, 222–227. - PubMed

Publication types

MeSH terms

Substances